Reports Q2 revenue $5M, consensus $714.29k. “As our PDUFA target action date is rapidly approaching, we are encouraged by our ongoing engagement with the FDA and are confident that the review of our NDA for LNZ100 is on track,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics (LENZ). “Additionally, with the recent execution of multiple licensing agreements in key geographies, we look forward to continuing the momentum to position LNZ100 with a global commercial footprint.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Lenz announces CORXEL submitted NDA for LNZ100 in China
- Lenz Therapeutics price target raised to $48 from $38 at H.C. Wainwright
- Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement
- LENZ Therapeutics Holds 2025 Annual Stockholders Meeting
- LENZ Therapeutics Prepares for LNZ100 Launch